| Vol. 10.00 – 5 January, 2022 |
| |
|
|
| Researchers identified highly activated, CD16+ T cells with increased cytotoxic functions in severe COVID-19. [Cell] |
| |
|
|
PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Scientists investigated the pharmacokinetics and efficacy of remdesivir administered by head dome inhalation in African green monkeys. [Science Translational Medicine] |
|
|
|
| A proteome map of COVID-19 skin was established and the susceptibility of human-induced pluripotent stem cell-derived skin organoids with hair follicles and nervous system was investigated, to SARS-CoV-2 infection. [Advanced Science] |
|
|
|
| A strong response was induced in monocytes and B cells, with a SARS-CoV-2–specific inflammatory gene cluster distinct from that seen in influenza A or Ebola virus-infected cocultures, and which reproduced deviations reported in blood or lung myeloid cells from COVID-19 patients. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Investigators showed that ACE2-overexpressing A549 cell-derived microparticles were a potential therapeutic agent against SARS-CoV-2 infection. [Cellular & Molecular Immunology] |
|
|
|
| Scientists reported the immunogenicity and protection induced in rhesus macaques by intramuscular injections of a virus-like particle bearing a SARS-CoV-2 spike protein vaccine candidate formulated with or without Adjuvant System 03 or cytidine-phospho-guanosine 1018. [Cellular & Molecular Immunology] |
|
|
|
| The authors reported that inhibitor of DNA binding protein 2 negatively regulated antiviral innate immune responses. [Science Signaling] |
| MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Investigators provided evidence to support the function of KLF14, a novel Krüppel-like transcription factor, in the regulation of glycolysis and the immune function of macrophages during sepsis. [Cellular & Molecular Immunology] |
|
|
|
| Lymphocytes and tissue sections of lymph node were collected from 11 HIV-1 positive antiretroviral therapy-naive and 19 HIV-1 negative donors. [Ebiomedicine] |
|
|
|
| The authors undertook a comprehensive study of T-follicular helper cells, along with B cells and antibody induction in children and adults with malaria. [Ebiomedicine] |
|
|
|
| Researchers reported the design of a multi-epitope vaccine against Hemagglutinin and Neuraminidase proteins of H7N9 Influenza A virus by prediction of Cytotoxic T lymphocyte, Helper T lymphocyte, IFN-γ and B cell epitopes. [Scientific Reports] |
|
|
|
| Scientists explored the role of marrow derived suppressor cells in the immune escape mechanism of Chlamydia trachomatis. [Immunology Letters] |
|
|
|
| Investigators identified immunodominant portions of four malaria vaccine candidate antigens using peripheral blood mononuclear cells from adults with life-long exposure to malaria parasites. [Vaccine] |
|
|
|
| Researchers established a semi-mechanistic population model simultaneously describing naïve and memory CD4+ T cell trajectories in 122 participants. [Immunity & Ageing] |
|
|
|
|
| | The authors examined distribution of the well-characterized +874 T/A IFN-γ and -509C/T TGF-β1 single nucleotide polymorphisms in Thai people living with HIV. [Journal of Medical Virology] |
|
|
|
| Mesenchymal stem cells appear to have the potential to contribute to the HIV-1 reservoir. Further studies are needed using techniques such as those used to prove that cluster of differentiation (CD)4+ T cells constitute an HIV-1 reservoir before a reservoir function can definitively be ascribed to MSCs. [Stem Cell Reviews and Reports] |
|
|
|
| Scientists summarize the physiological and pathological damage of SARS-CoV-2 to these systems and its molecular mechanisms followed by clinical manifestation. [International Journal of Biological Sciences] |
|
|
|
|
| Pfizer, Inc. and BioNTech SE announced a new research, development and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles. [Pfizer, Inc.] |
|
|
|
| VBI Vaccines, Inc. announced that the first patient has been dosed in a second Phase IIa/IIb clinical study evaluating VBI-2601, an immunotherapeutic candidate targeting chronic hepatitis B virus. [VBI Vaccines, Inc.] |
|
|
|
|
| January 21 -23, 2022 Austin, Texas, United States |
|
|
|
|
|
| Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| University of Florida – Gainesville, Florida, United States |
|
|
|
| Centre for Immunology & Infection Limited – Hong Kong, China |
|
|
|
| London School of Hygiene & Tropical Medicine – London, England, United Kingdom |
|
|
|
| King’s College London – London, England, United Kingdom |
|
|
|
|